Browse TRPA1

Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF12796 Ankyrin repeats (3 copies)
PF00520 Ion transport protein
Function

Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function (PubMed:25389312, PubMed:25855297). Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, cinnamaldehyde, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes (PubMed:25389312, PubMed:20547126). Is also activated by menthol (in vitro)(PubMed:25389312). Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312). May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system (By similarity).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006979 response to oxidative stress
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0009266 response to temperature stimulus
GO:0009409 response to cold
GO:0009581 detection of external stimulus
GO:0009582 detection of abiotic stimulus
GO:0009612 response to mechanical stimulus
GO:0010035 response to inorganic substance
GO:0019233 sensory perception of pain
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0033555 multicellular organismal response to stress
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0048265 response to pain
GO:0050907 detection of chemical stimulus involved in sensory perception
GO:0050951 sensory perception of temperature stimulus
GO:0050954 sensory perception of mechanical stimulus
GO:0050955 thermoception
GO:0050966 detection of mechanical stimulus involved in sensory perception of pain
GO:0050968 detection of chemical stimulus involved in sensory perception of pain
GO:0050974 detection of mechanical stimulus involved in sensory perception
GO:0050982 detection of mechanical stimulus
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051289 protein homotetramerization
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097553 calcium ion transmembrane import into cytosol
GO:1902656 calcium ion import into cytosol
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0005216 ion channel activity
GO:0005217 intracellular ligand-gated ion channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0015278 calcium-release channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022834 ligand-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
GO:0097603 temperature-gated ion channel activity
GO:0097604 temperature-gated cation channel activity
GO:0099604 ligand-gated calcium channel activity
Cellular Component GO:0032421 stereocilium bundle
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG hsa04750 Inflammatory mediator regulation of TRP channels
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-3295583: TRP channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRPA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRPA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9950.0673
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.5820.0724
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5840.435
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0490.933
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8210.649
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9220.669
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2650.696
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1930.842
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9580.359
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.8140.107
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.0610.0358
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3640.288
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141728.6028.60.0318
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103400400.497
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRPA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRPA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRPA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRPA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRPA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRPA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRPA1
Nametransient receptor potential cation channel, subfamily A, member 1
Aliases ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location8q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRPA1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TRPA1.
ID Name Drug Type Targets #Targets
DB00825MentholSmall MoleculeOPRK1, TRPA1, TRPM8, TRPV34
DB09061CannabidiolSmall MoleculeCACNA1G, CACNA1H, CACNA1I, CHRNA7, CNR1, CNR2, GLRA1, GLRA1, GLRA3 ......25